Iris Romero, M.D., M.S. - 2007 Young Investigator Award
"Bazedoxifene as Chemoprophylaxis for Ovarian Cancer"
Awarded a $50,000 2007 Young Investigator Award
Ovarian cancer is an insidious and devastating disease. Given the limitations of screening and our current inability to cure ovarian cancer, prevention is the key to reduction in mortality. Epidemiological and in vitro studies demonstrate that estrogen may increase the risk of ovarian cancer. Therefore blocking estrogen stimulation at the level of the ovarian surface epithelium may provide protection against ovarian cancer. Selective estrogen receptor modulators (SERMs) have been widely used in breast cancer prophylaxis but there role in ovarian cancer is less clear. Bazedoxifene is a novel SERM that has been shown to inhibit estradiol induced human breast cancer cell proliferation without stimulating the endometrium. Our hypothesis for this grant is that Bazedoxifene with its estrogen inhibition might be useful as chemoprophylactic agent for ovarian cancer. To explore this we will use a genetic mouse model of ovarian cancer to evaluate the effect of Bazedoxifene on tumor burden, cell signaling, apoptosis, and invasion.
"I owe a great deal to the Cancer Research Foundation for giving me a head start. This financial help made the difference between my getting a fast and successful start, and my other wise struggling to obtain the necessary funds to get my research program started."Elaine Fuchs, Ph.D.
Professor, Departments of Medicine and Molecular Genetics and Cell Biology and Human Genetics University of Chicago
April 30, 2010